OTCPK:ABMC

Stock Analysis Report

Executive Summary

American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Risks

  • American Bio Medica is not covered by any analysts.

Share Price & News

How has American Bio Medica's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.2%

OTCPK:ABMC

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-15.8%

OTCPK:ABMC

8.7%

US Medical Equipment

1.7%

US Market

ABMC underperformed the Medical Equipment industry which returned 8.7% over the past year.

ABMC underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

ABMCIndustryMarket
7 Day8.2%-1.2%1.2%
30 Day8.2%1.4%4.9%
90 Day4.6%4.8%3.7%
1 Year-15.8%-15.8%9.6%8.7%3.9%1.7%
3 Year-41.7%-41.7%70.8%65.5%47.2%37.7%
5 Year-36.3%-36.3%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is American Bio Medica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is American Bio Medica undervalued based on future cash flows and its price relative to the stock market?


Intrinsic Value Based on Future Cash Flows

American Bio Medica's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

American Bio Medica's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

American Bio Medica is loss making, we can't compare its value to the US Medical Equipment industry average.

American Bio Medica is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for American Bio Medica, we can't assess if its growth is good value.


Price Based on Value of Assets

American Bio Medica has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.


Next Steps

Future Growth

How is American Bio Medica expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as American Bio Medica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of ABMC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access American Bio Medica's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has American Bio Medica performed over the past 5 years?

-27.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

American Bio Medica does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare American Bio Medica's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare American Bio Medica's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if American Bio Medica has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if American Bio Medica has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if American Bio Medica improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is American Bio Medica's financial position?


Financial Position Analysis

American Bio Medica's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

American Bio Medica's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

American Bio Medica has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if American Bio Medica's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

American Bio Medica has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making American Bio Medica has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making American Bio Medica has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 87.6% per year.


Next Steps

Dividend

What is American Bio Medica's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate American Bio Medica's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate American Bio Medica's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as American Bio Medica has not reported any payouts.

Unable to verify if American Bio Medica's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as American Bio Medica has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of American Bio Medica's salary, the management and board of directors tenure and is there insider trading?

6.5yrs

Average management tenure


CEO

Melissa Waterhouse (48yo)

5.9yrs

Tenure

US$164,090

Compensation

Ms. Melissa A. Waterhouse has been the Chief Executive Officer and Principal Financial Officer of American Bio Medica Corp. since June 19, 2014 and served as its Principal Accounting & Financial Officer. M ...


CEO Compensation Analysis

Melissa's remuneration is lower than average for companies of similar size in United States of America.

Melissa's compensation has increased whilst company is loss making.


Management Age and Tenure

6.5yrs

Average Tenure

65yo

Average Age

The average tenure for the American Bio Medica management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.8yrs

Average Tenure

54.5yo

Average Age

The tenure for the American Bio Medica board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$50,00025 Jan 19
Revach Capital Management LLC
EntityCompany
Shares500,000
Max PriceUS$0.10
BuyUS$3,11925 Jan 19
Chaim Davis
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares38,993
Max PriceUS$0.08

Ownership Breakdown


Management Team

  • Douglas Casterlin (71yo)

    Vice President of Operations

    • Tenure: 7.2yrs
    • Compensation: US$126.73k
  • Melissa Waterhouse (48yo)

    CEO, Principal Financial Officer & Director

    • Tenure: 5.9yrs
    • Compensation: US$164.09k
  • Jean Neff (76yo)

    Corporate Secretary & Independent Director

    • Tenure: 11.6yrs
    • Compensation: US$5.35k
  • J. Urquhart (65yo)

    Controller

    • Tenure: 8yrs
  • Scott Hutton (62yo)

    Vice President of Sales & Marketing

    • Tenure: 4.8yrs

Board Members

  • Edmund Jaskiewicz (95yo)

    Chairman Emeritus

    • Tenure: 0yrs
    • Compensation: US$12.40k
  • Melissa Waterhouse (48yo)

    CEO, Principal Financial Officer & Director

    • Tenure: 5.9yrs
    • Compensation: US$164.09k
  • Jean Neff (76yo)

    Corporate Secretary & Independent Director

    • Tenure: 11.6yrs
    • Compensation: US$5.35k
  • Peter Jerome (50yo)

    Director

    • Tenure: 1.7yrs
    • Compensation: US$9.10k
  • Chaim Davis (41yo)

    Chairman of the Board

    • Tenure: 1.5yrs
    • Compensation: US$10.60k
  • Diane Generous (59yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$9.10k

Company Information

American Bio Medica Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: American Bio Medica Corporation
  • Ticker: ABMC
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.465m
  • Shares outstanding: 32.55m
  • Website: https://www.abmc.com

Number of Employees


Location

  • American Bio Medica Corporation
  • 122 Smith Road
  • Kinderhook
  • New York
  • 12106
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABMCOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 1990

Biography

American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in uri ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/14 23:31
End of Day Share Price2019/09/12 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.